Analysis of bioMARKer Distribution and Individual Reproducibility Under Rivaroxaban Treatment in Japanese Patients with Non-Valvular Atrial Fibrillation (R-MARK Study, CVI ARO2)

被引：3

作者：

Hirota, Naomi ^{[1
]}

Suzuki, Shinya ^{[1
]}

Yamasaki, Masao ^{[2
]}

Matsumoto, Naoki ^{[3
]}

Ajiki, Kousuke ^{[4
]}

Kasao, Masashi ^{[5
]}

Hiroi, Yukio ^{[6
]}

Takizawa, Masataka ^{[7
]}

Mitani, Haruo ^{[8
]}

Fukatsu, Tohru ^{[9
]}

Hayami, Noriyuki ^{[10
]}

Yamashita, Takeshi ^{[1
]}

机构：

[1] Cardiovasc Inst, Dept Cardiovasc Med, Tokyo, Japan

[2] NTT Med Ctr, Dept Cardiol, Tokyo, Japan

[3] St Marianna Univ, Sch Med, Dept Pharmacol, Kawasaki, Kanagawa, Japan

[4] JR Tokyo Gen Hosp, Dept Cardiol, Tokyo, Japan

[5] Tokyo Metropolitan Police Hosp, Dept Cardiol, Tokyo, Japan

[6] Natl Ctr Global Hlth & Med, Ctr Hosp, Dept Cardiol, Tokyo, Japan

[7] Japanese Red Cross Med Ctr, Dept Cardiol, Tokyo, Japan

[8] Toranomon Gen Hosp, Dept Cardiol, Tokyo, Japan

[9] Tokyo Teishin Hosp, Dept Cardiovasc Med, Tokyo, Japan

[10] Teikyo Univ Hosp, Dept Internal Med 4, Kawasaki, Kanagawa, Japan

来源：

INTERNATIONAL HEART JOURNAL | 2020年 / 61卷 / 04期

关键词：

Oral anticoagulation; Plasma concentration; On-therapy range; FACTOR-XA INHIBITOR; ANTICOAGULANT ACTIVITY; WARFARIN;

D O I：

10.1536/ihj.20-041

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The "on-therapy range" of direct oral anticoagulants is the 90% interval of drug concentration. Previously, we reported the on-therapy range of rivaroxaban in a single-center cohort. The present study aimed to confirm the range and intraindividual reproducibility in a multicenter cohort. Eligible patients with non-valvular atrial fibrillation under rivaroxaban treatment for prevention of ischemic stroke were enrolled from nine institutes in Tokyo, Japan, between June 2016 and May 2017 (n = 324). The first and second (three months later) blood samples both taken within 1-5 hours after rivaroxaban intake were analyzed (n = 219). Plasma concentration of rivaroxaban (PC-Riv) and prothrombin time (PT) with five reagents were measured. The 90% interval of PC-Riv was 47.3-532.9 ng/mL. The 90% interval of PT measured with RecombiPlasTin 2G was 11.8-22.3 seconds, the widest range among the five reagents examined. PC-Riv reproducibility within a 90% interval was evaluated bidirectionally (first-to-second and second-to-first), and 92.4% of samples were reproducible. The change rate (CR) of PC-Riv between two samplings ranged widely, and high CR (>= 54.3%, cutoff for predicting non-reproducibility) was predicted by concomitant drugs (non-dihydropyridine calcium antagonist and thiazide) and mitral regurgitation. We reported the on-therapy range of rivaroxaban in a multicenter cohort. This range was consistent with that of a single-center cohort and was highly reproducible within three months in daily clinical practice. However, caution is necessary regarding several factors that may affect the intraindividual variation of PC-Riv.

引用

页码：695 / 704

页数：10

共 20 条

[1] Laboratory Measurement of the Anticoagulant Activity of the Non-Vitamin K Oral Anticoagulants [J].